MX2010009642A - Metodos de tratamiento utilizando infusion continua prolongada de belinostat. - Google Patents

Metodos de tratamiento utilizando infusion continua prolongada de belinostat.

Info

Publication number
MX2010009642A
MX2010009642A MX2010009642A MX2010009642A MX2010009642A MX 2010009642 A MX2010009642 A MX 2010009642A MX 2010009642 A MX2010009642 A MX 2010009642A MX 2010009642 A MX2010009642 A MX 2010009642A MX 2010009642 A MX2010009642 A MX 2010009642A
Authority
MX
Mexico
Prior art keywords
prolonged continuous
belinostat
methods
continuous infusion
treatment employing
Prior art date
Application number
MX2010009642A
Other languages
English (en)
Spanish (es)
Inventor
Maxwell Sehested
Peter Buhl Jensen
Nis Niseen
Original Assignee
Topotarget As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget As filed Critical Topotarget As
Publication of MX2010009642A publication Critical patent/MX2010009642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2010009642A 2008-03-07 2009-03-06 Metodos de tratamiento utilizando infusion continua prolongada de belinostat. MX2010009642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3463508P 2008-03-07 2008-03-07
PCT/IB2009/005044 WO2009109861A1 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of belinostat

Publications (1)

Publication Number Publication Date
MX2010009642A true MX2010009642A (es) 2010-09-22

Family

ID=40691318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009642A MX2010009642A (es) 2008-03-07 2009-03-06 Metodos de tratamiento utilizando infusion continua prolongada de belinostat.

Country Status (14)

Country Link
US (1) US20110003777A1 (cg-RX-API-DMAC10.html)
EP (1) EP2262493B1 (cg-RX-API-DMAC10.html)
JP (1) JP5615189B2 (cg-RX-API-DMAC10.html)
CN (1) CN102083428A (cg-RX-API-DMAC10.html)
AU (1) AU2009220942B2 (cg-RX-API-DMAC10.html)
CA (1) CA2717207A1 (cg-RX-API-DMAC10.html)
DK (1) DK2262493T3 (cg-RX-API-DMAC10.html)
EA (1) EA022880B1 (cg-RX-API-DMAC10.html)
ES (1) ES2536208T3 (cg-RX-API-DMAC10.html)
MX (1) MX2010009642A (cg-RX-API-DMAC10.html)
PL (1) PL2262493T3 (cg-RX-API-DMAC10.html)
PT (1) PT2262493E (cg-RX-API-DMAC10.html)
SI (1) SI2262493T1 (cg-RX-API-DMAC10.html)
WO (1) WO2009109861A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
MX357935B (es) * 2012-04-27 2018-07-31 Sun Pharmaceutical Ind Ltd Solución de gemcitabina lista para infundir.
CN103839548B (zh) * 2012-11-26 2018-06-01 腾讯科技（北京）有限公司 一种语音交互方法、装置、系统和移动终端

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
WO2000021979A2 (en) * 1998-10-13 2000-04-20 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide and their use as histone deacetylase inhibitor
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
KR20100035666A (ko) * 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
CA2423868C (en) * 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP2292593A3 (en) * 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002074298A1 (en) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
RU2301666C2 (ru) * 2002-01-11 2007-06-27 Маттиас Рат Обладающий питательными свойствами фармацевтический состав на основе полифенолов и его использование при лечении рака
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
HRP20060080A2 (en) * 2003-08-26 2006-07-31 Sloan-Kettering Institute For Cancer Research Method of treating cancer with hdac inhibitors
WO2005052143A2 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
EP1689445B1 (de) * 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
CA2557568C (en) * 2004-02-27 2014-05-27 Jane Trepel Pharmacodynamic assays using flow cytometry
EP1591109B1 (en) * 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
WO2006014024A1 (ja) * 2004-08-06 2006-02-09 Ono Pharmaceutical Co., Ltd. 精神神経系疾患治療剤
CN101001851B (zh) * 2004-08-09 2011-04-20 安斯泰来制药有限公司 具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物
US8889742B2 (en) * 2004-11-30 2014-11-18 The Trustees Of The University Of Pennsylvania Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
NZ589276A (en) * 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
SI1901729T1 (sl) * 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
CA2621406A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8530493B2 (en) * 2006-02-22 2013-09-10 4Sc Ag Indolopyridines as Eg5 kinesin modulators
AU2007217562A1 (en) * 2006-02-22 2007-08-30 4Sc Ag Indolopyridines as EG5 kinesin modulators
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US8338482B2 (en) * 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US7915245B2 (en) * 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
WO2008101121A2 (en) * 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
GB2454118B (en) * 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2009137649A2 (en) * 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
EA201070913A1 (ru) 2011-04-29
AU2009220942A8 (en) 2012-08-30
JP5615189B2 (ja) 2014-10-29
EA022880B1 (ru) 2016-03-31
DK2262493T3 (en) 2015-04-27
HK1152247A1 (en) 2012-02-24
AU2009220942B2 (en) 2015-05-28
AU2009220942A1 (en) 2009-09-11
PL2262493T3 (pl) 2015-08-31
EP2262493A1 (en) 2010-12-22
WO2009109861A1 (en) 2009-09-11
ES2536208T3 (es) 2015-05-21
EP2262493B1 (en) 2015-02-25
US20110003777A1 (en) 2011-01-06
SI2262493T1 (sl) 2015-07-31
PT2262493E (pt) 2015-06-02
JP2011513378A (ja) 2011-04-28
CA2717207A1 (en) 2009-09-11
CN102083428A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
MX2023002076A (es) Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica.
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
PH12018502259A1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2015008860A (es) Inhibidores de 3-(benzoimidazol-2-il)-indazol de la senda de señalizacion de wnt y usos terapeuticos de los mismos.
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
PH12016501835A1 (en) 5-substituted indazole -3- carboxamides and preparation and use thereof
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2013000301A (es) Factores quimericos de coagulacion.
PH12017501588A1 (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
IN2014CN02646A (cg-RX-API-DMAC10.html)
MY186456A (en) Quinazoline carboxamide azetidines
CR20200291A (es) Composiciones y métodos para el tratamiento de enfermedades metabólicas
MX2015003800A (es) Terapia de combinacion mediante el uso de belinostat y trabetedina.
PH12020551300A1 (en) 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof
MY193343A (en) Biosynthetic heparin
AU2009220942A8 (en) Methods of treatment employing prolonged continuous infusion of Belinostat
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
SA515360377B1 (ar) نظائر خيمرية من سوماتوستاتين- دوبامين
EA201170885A1 (ru) Новые производные ретиноидов, обладающие цитотоксическими и/или антиангиогенными свойствами
RU2013130449A (ru) Способ комбинированного лечения рака прямой кишки

Legal Events

Date Code Title Description
FG Grant or registration